2026-04-19T11:38:25Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2213732025-12-05T12:13:26Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Villacieros Álvarez, Javier author Espejo Ruiz, Carmen author Arrambide, Georgina author Dinoto, Alessandro author Mulero Carrillo, Patricia author Rubio Flores, Laura author Nieto González, Pablo author Alcalá, Carmen author Meca Lallana, José E. author Millan Pascual, Jorge author Martínez García, Pedro author Bernard Valnet, Raphael author González Suárez, Inés author Orviz García, Aída author Téllez Pérez, Raquel author Navarro Cantó, Laura author Presas Rodríguez, Silvia author Martínez Yélamos, Sergio author Cuello, Juan Pablo author Alonso Torres, Ana María author Piñar Morales, Raquel author Álvarez Bravo, Gary author Benyahya, Lakhdar author Trouillet Assant, Sophie author Dyon Tafan, Virginie author Froment Tilikete, Caroline author Ruet, Aurélie author Bourre, Bertrand author Deschamps, Romain author Papeix, Caroline author Maillart, Elisabeth author Kerschen, Philippe author Ayrignac, Xavier author Rovira, Àlex author Auger Acosta, Cristina author Audoin, Bertrand author Montalbán Gairín, Xavier author Tintoré Subirana, Mar author Mariotto, Sara author Cobo Calvo, Álvaro author Marignier, Romain author 2025-06-04T09:12:59Z 2025-06-04T09:12:59Z 2025-03-01 2025-05-16T11:41:03Z Objectives To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. Methods This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (<= 3 months from disease onset) and follow-up (>= 6 months from the baseline), and age-matched and time to sampling-matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Results Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non-optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). Discussion This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions. Neuroimmunologia Autoanticossos Neuroimmunology Autoantibodies Profile and Usefulness of Serum Cytokines to Predict Prognosis in Myelin Oligodendrocyte Glycoprotein Antibody−Associated Disease